This study showed an enhanced efficacy of enzalutamide when combined with the STAT3 inhibitor GPB730 in prostate cancer cells which have not previously been exposed to enzalutamide and focuses on the intrinsic resistance to enzalumide treatment. This evidence concerns the gene STAT3 and prostate cancer.